Systematic reviews of wound care management: (3) Antimicrobial agents for chronic wounds; (4) diabetic foot ulceration

Health Technology Assessment

Volumn 4, Issue 21, 2000, Pages

  O'Meara, S ^a   Cullum, N ^a   Majid, M ^a   Sheldon, T ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL; ACTIVATED CARBON; ALLOPURINOL; ANTIBIOTIC AGENT; BENZOYL PEROXIDE; CIPROFLOXACIN; COLLAGEN GEL; COPPER COMPLEX; CRYSTAL VIOLET; DERMAMEND; DIMETHYL SULFIDE; DUODERM; EOSIN PLUS CHLOROXYLENOL; GENTAMICIN; GLYCYLHISTIDYLLYSINE; GROWTH FACTOR; HEXACHLOROPHENE; HYDROGEN PEROXIDE; ILOPROST; KETANSERIN; LEVAMISOLE; METRONIDAZOLE; PHENYTOIN; POLYNOXYLIN; POVIDONE IODINE; POVIDONE IODINE PLUS SUGAR; PROSTAGLANDIN; PROSTAGLANDIN E1; PSEUDOMONIC ACID; SILVER ZINC ALLANTOINIC ACID; SULFADIAZINE SILVER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CALLUS; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DECUBITUS; DIABETIC FOOT; EXCISION; FOOT AMPUTATION; HEALTH PROGRAM; HUMAN; HYDROCOLLOID; HYPERBARIC OXYGEN; LEG ULCER; PATIENT EDUCATION; PILONIDAL SINUS; PODIATRY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; SCREENING; SHOE; SKIN TRANSPLANTATION; SURGICAL WOUND; SUTURE; WOUND; WOUND DRESSING;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; BIOMEDICAL TECHNOLOGY; CHRONIC DISEASE; DIABETIC FOOT; HUMANS; QUALITY ASSURANCE, HEALTH CARE; SURGICAL WOUND INFECTION; WOUNDS AND INJURIES;

EID: 0034494502     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Prevalence of foot pathology and lower extremity complications in a diabetic outpatient clinic
2. Metatarsal head resection for diabetic foot ulcers
3. Medical risk factors in diabetic patients with foot ulcers and severe peripheral vascular disease and their influence on outcome
4. Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid (RGD) peptide matrix
5. Blood flow in the diabetic neuropathic foot
6. Insensitivity, limited joint mobility and plantar ulcers in patients with diabetes mellitus
7. Management of diabetic midfoot ulcers
8. The nonhealing diabetic ulcer - a major cause for limb loss
9. Experience in a multidisciplinary diabetic foot clinic
10. Long term prognosis for diabetic patients with foot ulcers
11. Peripheral vascular disease
12. The use of orthotic devices to correct plantar callus in people with diabetes
13. Pathways to diabetic limb amputation: Basis for prevention
14. Preventing leg and foot complications
15. Lower extremity amputation in people with diabetes: Epidemiology and prevention
16. The diabetic foot
17. Conference report. Diabetes mellitus in Europe: A problem at all ages and in all countries. A model for prevention and self care
18. Improved survival of the diabetic foot: The role of a specialised foot clinic
19. Diabetic foot lesions: Pathogenesis and management
20. Diabetic foot care
21. A controlled trial to increase office visits and reduce hospitalisations of diabetic patients
22. Economic aspects of the diabetic foot
23. The prevalence of foot lesions - a community survey
24. A team approach to diabetic foot care - the Manchester experience
25. Randomised controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers
26. Use of plantar casts in the management of diabetic neuropathic foot ulcers
27. The total contact cast for the management of plantar ulceration of the foot
28. Stimulation of repair in chronic, nonhealing cutaneous ulcers using platelet-derived wound healing formula
29. Randomised prospective double-blind trial in healing chronic diabetic foot ulcers: CT-102 activated platelet supernatant, topical versus placebo
30. Growth factors and wound healing. II. Role in normal and chronic wound healing
31. Wound therapy: Growth factors as agents to promote healing
32. Treatment of four arteriolar ulcers with topical 2% ketanserin
33. Topical ketanserin in the treatment of decubitus ulcers: A double blind study with 2% ketanserin ointment against placebo
34. Morphological effects of serotonin and ketanserin on embryonic chick skin in vitro
35. The dysvascular foot: A system for diagnosis and treatment
36. Repetitive stress in the development of diabetic foot ulcers
37. You see what you look for and recognise what you know
38. The effect of callus removal on dynamic plantar foot pressures in diabetic patients
39. The diabetic foot: Impact of a foot clinic
40. Footwear and orthoses for diabetic patients
41. Manufactured shoes in the prevention of diabetic foot ulcers
42. Evaluation of the impact of podiatrist care in the primary prevention of foot problems in diabetic subjects
43. Blood flow in the perimalleolar skin in relation to posture in patients with venous hypertension
44. Elastic stockings in diabetic microangiopathy - Long term clinical and microcirculatory evaluation
45. Comparative study of diabetes knowledge among juvenile diabetics and their parents
46. Randomised, controlled trial of diabetic patient education: Improved knowledge without improved metabolic status
47. Evaluation of a structured teaching and treatment programme for type 2 diabetes in general practice in a rural area of Austria
48. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
49. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus
50. Prevention of amputation by diabetic education
51. Evaluation of a diabetic foot screening and protection programme
52. Reduction of plantar pressure with the rigid relief orthosis
53. Total contact casting in treatment of diabetic plantar ulcers. Controlled clinical trial
54. Connective tissue in diabetes mellitus: Biochemical alterations of the intercellular matrix with special reference to proteoglycans
55. Use of Dermagraft, a cultured human dermis to treat diabetic foot ulcers
56. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers
57. A human dermal replacement for the treatment of diabetic foot ulcers
58. Evaluation of the cost-effectiveness of a tissue engineered human dermal replacement in the treatment of diabetic foot ulcers in the UK
59. Low hyperbaric oxygen therapy in the management of leg ulcers
60. Adjunctive systemic hyperbaric oxygen therapy in the treatment of severe prevalently ischemic diabetic foot ulcers
61. 2 serotonergic receptors
62. Serotonergic mechanisms in hypertension: Focus on the effects of ketanserin
63. International study of ketanserin in Raynaud's phenomenon
64. 2 receptor antagonist (ketanserin)
65. Topical ketanserin accelerates the wound healing process in decubitus, arterial and diabetic skin ulcers
66. Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers
67. Ketanserin in the treatment of diabetic foot ulcers with severe PVD
68. Iloprost in der behandlung ischamischer gewebslasionen bei diabetikern
69. 1)-mimetics in severe PVD
70. Prostanoids in therapy of peripheral arterial occlusive disease
71. 1-controlled multicentre trials in patients with diabetic neuropathy and leg ulcers
72. Growth factors: Their biology and promise in dermatologic diseases and tissue repair
73. Growth factors and wound healing: Biochemical properties of growth factors and their receptors
74. Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats
75. Role of platelet-derived growth factor in wound healing
76. Human fibroblast-derived growth factor is a mitogen and chemoattractant for endothelial cells
77. Recombinant basic fibroblast growth factor accelerates wound healing
78. Basic fibroblast growth factor stimulation of epidermal wound healing in pigs
79. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice
80. Integrins
81. Integrins: Versality, modulation, and signalling in cell adhesion
82. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
83. A randomised controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, non-healing diabetic wounds
84. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot randomised double-blind placebo-controlled study
85. Allevyn vs Sorbsan in the treatment of diabetic foot ulcers
86. Comparing two dressings in the treatment of diabetic foot ulcers
87. Diabetic foot infection controlled by immuno-modulating hydrogel containing 65% glycerine - Presentation of a clinical trial
88. Clinical evaluation of a semiperemeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcer
89. Comparing two wound dressings for the treatment of neuropathic diabetic foot ulcers
90. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers
91. Effects of dimethylsulfoxide (DMSO) on prostaglandin synthetase
92. DMSO inhibits platelet aggregation in partially obstructed canine coronary vessels
93. Protection of the ischemic heart with DMSO alone or DMSO with hydrogen peroxide
94. Alleviation of experimental ischemic renal failure by dimethylsulfoxide
95. The protective effect of dimethylsulfoxide in experimental ischemia of the intestines
96. Treatment of diabetic perforating ulcers (mal perforant) with local dimethylsulfoxide
97. An in vivo assay for chemoattractant activity
98. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-listidyl-L-lysine copper
99. Topical phenytoin in diabetic foot ulcers
100. Controlled trial of Iodosorb in chronic venous ulcers
101. A randomised trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers
102. Cavity foot ulcers in diabetic patients: A comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial
103. Topical treatment of necrotic foot ulcers in diabetic patients: A comparative trial of Duoderm and MeZinc
104. Choice of antibiotic therapy in diabetic foot lesions
105. Assessment and management of foot disease in patients with diabetes
106. Outpatient management of uncomplicated lower-extremity infections in diabetic patients
107. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: A controlled trial
108. The debridement of chronic wounds: A systematic review
109. Intensive education improves knowledge, compliance and foot problems in type 2 diabetes
110. Hyperbaric oxygen in diabetic gangrene treatment
111. Hyperbaric oxygen therapy in patients with foot ulcers secondary to diabetes mellitus
112. Hyperbaric oxygen therapy in diabetic gangrene
113. Treatment of limb threatening ischaemia with intravenous iloprost: A randomised double blind placebo controlled study
114. Multicentre evaluation of NuGel wound dressing in full thickness chronic wounds of the lower extremities
115. Lyophilized collagen in the treatment of diabetic foot ulcers
116. Application of Opsite film: A new and effective treatment of painful diabetic neuropathy
117. The use of kalstostat in the treatment of ulceration in the diabetic foot
118. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections
119. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen
120. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both
121. Hemorheologic approach in the treatment of diabetic foot ulcers
122. Use of ciprofloxacin in the treatment of serious skin and skin structure infections
123. Amdinocillin plus cefoxitin vs cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections)
124. Treatment and long term follow up of foot infections in patients with diabetes or ischaemia: A randomised prospective double blind comparison of cefoxitin and ceftizoxine
125. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb threatening foot infections in diabetic patients
126. Treatment of hospitalised patients with complicated skin and skin structure infections: Double blind randomised multicentre study of piperacillin-tazobactam versus ticarcillin-clavulanate
127. Electrical nerve stimulation improves healing of diabetic ulcers
128. The role of footwear in the prevention of foot lesions in patients with NIDDM
129. Foot care: Knowledge retention and self care practices
130. A randomised study of the effects of a home diabetes education programme